Chukwunonso K Nwabufo (Chukwunonso Nwabufo)

Years Active: 2020-2023
Publications (10 Years): 5

Gilead Alberta ULC

University of Saskatchewan College of Pharmacy and Nutrition (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Gilead Alberta ULC Mar 18o 2019

Canada

Senior Research Associate I :: Analytical Chemistry

Education History

University of Saskatchewan College of Pharmacy and Nutrition Jan 4o 2017 - Feb 25o 2019

Canada

MSC :: Pharmacy

Publications

Chukwunonso K Nwabufo
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations. Cancer chemotherapy and pharmacology (2023)
Chukwunonso K Nwabufo, Omozojie P Aigbogun
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease. Journal of neurology 269 (11) (2022)
Laura E Russell, Yitian Zhou, Ahmed A Almousa, Jasleen K Sodhi, Chukwunonso K Nwabufo, Volker M Lauschke
Pharmacogenomics in the era of next generation sequencing - from byte to bedside. Drug metabolism reviews 53 (2) (2021)
Chukwunonso K Nwabufo, Anas El-Aneed, Ed S Krol
Tandem mass spectrometric analysis of novel caffeine scaffold-based bifunctional compounds for Parkinson's disease. Rapid communications in mass spectrometry : RCM 33 (23) (2020)
Laura E Russell, Mary Alexandra Schleiff, Eric Gonzalez, Aaron G Bart, Fabio Broccatelli, Jessica H Hartman, W Griffith Humphreys, Volker M Lauschke, Iain Martin, Chukwunonso K Nwabufo, Bhagwat Prasad, Emily E Scott, Matthew Segall, Ryan Takahashi, Mitchell E Taub, Jasleen K Sodhi
Advances in the study of drug metabolism - symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX). Drug metabolism reviews 52 (3) (2020)

Chukwunonso K Nwabufo.css-eqlu8i{font-size:small;padding-left:4px;} (Chukwunonso Nwabufo)